干扰素与胸腺肽联合治疗慢性乙型肝炎前C区变异株感染的疗效观察  

Efficacy of Combination Therapy of IFNα-2b and Thymosin on CHB Patients with HBV Pre-C Mutants

作　　者：江晓平[1] 孙秋林[1] 叶珺[1] 叶英[1] 尹华发[1] 

机构地区：[1]安徽医科大学第一附属医院传染病科,合肥230022

出　　处：《安徽医科大学学报》2002年第6期454-456,共3页Acta Universitatis Medicinalis Anhui

基　　金：安徽医科大学第一附属医院青年科研基金资助项目 ( 99-21);安徽省科委重点科研项目 ( 990 2 2 0 0 9)

摘　　要：目的　了解干扰素联合胸腺肽治疗慢性乙型肝炎前C区变异株感染的疗效。方法　 6 3例患者随机分为A、B两组。A组用干扰素α 2b 3 0× 10 6U ,肌注 ,每日 1次 ,14d后改隔日 1次至 6个月 ,胸腺肽 40～ 5 0mg ,静滴 ,每日 1次 ,1～ 2月后改肌注或口服至 3个月。B组单用干扰素α 2b ,方法同A组。比较两组血清HBVDNA、HBsAg阴转率和ALT复常率。结果　A、B两组治疗结束时HBVDNA阴转率分别为 45 16 %和 43 75 % (P >0 0 5 ) ,9个月后分别为77 42 %和 5 3 13 % (P <0 0 5 ) ,远期疗效联合治疗组优于单用干扰素组。两组治疗结束时均无HBsAg阴转者。ALT复常率A组为 48 39% ,B组为 5 0 % ,两组差异无显著性。结论　干扰素α 2b联合胸腺肽治疗乙型肝炎病毒前C区变异株感染远期疗效优于单用干扰素组 ,但疗效仍不够理想。Objective To evaluate the therapeutic effects of interferon α(IFNα-2b) combined with thymosin on chronic hepatitis B(CHB) patients with HBV pre-core mutants. Methods 63 patients were randomly divided into group A and B. Patients in both groups received IFNα-2b for six months. In addition, patients in group A also received thymosin for 3 months. Results At the end of treatment, fourteen patients in group A(45.16%) and fourteen patients in group B(43.75%) were serum HBV DNA negative (P>0.05). But 77.42% of patients in group A and 53.13% of patients in group B became serum HBV DNA negative nine months later(χ 2=4.0886,P<0.05).No patients of the 2 groups became serum HBsAg negative. 15 patients in group A and 16 patients in group B had normal serum ALT after treatment(P>0.05).Conclusion Long-term therapeutic efficacy of IFNα-2b combined with thymosin on CHB patients with HBV pre-core mutants is better than IFN-α alone.

关 键 词：干扰素 胸腺肽 联合治疗 乙型肝炎前C区变异株感染 疗效观察 

分 类 号：R512.620.5[医药卫生—内科学]